PL379704A1 - Środek farmaceutyczny jako stała postać dawkowana i sposób jego wytwarzania - Google Patents

Środek farmaceutyczny jako stała postać dawkowana i sposób jego wytwarzania

Info

Publication number: PL379704A1
Authority: PL; Poland
Prior art keywords: dosage form; solid dosage; manufacturing; pharmaceutical composition; desmopressin
Prior art date: 2003-07-25

Application number

PL379704A

Other languages

English (en)

Inventor

Hakan Lomryd

Helena Nicklasson

Lars-Erik Olsson

Original Assignee

Ferring B.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-25

Filing date

2004-07-19

Publication date

2006-11-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34117527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL379704(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-07-19 Application filed by Ferring B.V. filed Critical Ferring B.V.

2006-11-13 Publication of PL379704A1 publication Critical patent/PL379704A1/pl

Links

108010000437 Deamino Arginine Vasopressin Proteins 0.000 title abstract 3
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 title abstract 3
229960004281 desmopressin Drugs 0.000 title abstract 3
239000007909 solid dosage form Substances 0.000 title abstract 3
238000004519 manufacturing process Methods 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 4
239000004480 active ingredient Substances 0.000 abstract 2
239000003085 diluting agent Substances 0.000 abstract 1
239000008187 granular material Substances 0.000 abstract 1
239000000314 lubricant Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL379704A 2003-07-25 2004-07-19 Środek farmaceutyczny jako stała postać dawkowana i sposób jego wytwarzania PL379704A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/626,857 US7022340B2 (en)	2003-07-25	2003-07-25	Pharmaceutical composition as solid dosage form and method for manufacturing thereof
EP03016945A EP1500390B1 (en)	2003-07-25	2003-07-25	Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof

Publications (1)

Publication Number	Publication Date
PL379704A1 true PL379704A1 (pl)	2006-11-13

Family

ID=34117527

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL379704A PL379704A1 (pl)	2003-07-25	2004-07-19	Środek farmaceutyczny jako stała postać dawkowana i sposób jego wytwarzania

Country Status (21)

Country	Link
US (1)	US7022340B2 (pl)
EP (1)	EP1500390B1 (pl)
JP (1)	JP4430673B2 (pl)
KR (1)	KR20050104331A (pl)
AT (1)	ATE301990T1 (pl)
AU (1)	AU2004260625B2 (pl)
BR (1)	BRPI0412905A (pl)
CA (1)	CA2490335C (pl)
DE (1)	DE60301351T2 (pl)
DK (1)	DK1500390T3 (pl)
ES (1)	ES2243840T3 (pl)
IL (1)	IL187591A0 (pl)
MX (1)	MXPA06000903A (pl)
NO (1)	NO327328B1 (pl)
NZ (1)	NZ544104A (pl)
PL (1)	PL379704A1 (pl)
PT (1)	PT1500390E (pl)
RU (1)	RU2303439C2 (pl)
SI (1)	SI1500390T1 (pl)
TW (1)	TWI268782B (pl)
WO (1)	WO2005011640A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0210397D0 (en) *	2002-05-07	2002-06-12	Ferring Bv	Pharmaceutical formulations
US7094545B2 (en) *	2003-04-30	2006-08-22	Ferring Bv	Pharmaceutical composition as solid dosage form and method for manufacturing thereof
CN1826099B (zh) *	2003-07-25	2010-06-09	凡林有限公司	固体剂型药物组合物及其制造方法
PT1530967E (pt) *	2003-11-13	2006-09-29	Ferring Bv	Embalagem blister e uma forma de dosagem solida que compreende desmopressina.
CA2490601C (en) *	2003-12-29	2006-05-02	Ferring B.V.	Method for preparing solid dosage form of desmopressin
US7018653B2 (en) *	2003-12-29	2006-03-28	Ferring B.V.	Method for preparing solid dosage form of desmopressin
SE0600482L (sv) *	2006-03-02	2006-11-14	Ferring Int Ct Sa	Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
WO2009021007A1 (en)	2007-08-06	2009-02-12	Serenity Pharmaceuticals Corporation	Methods and devices for desmopressin drug delivery
ES2319054B1 (es)	2007-08-06	2010-02-12	Gp Pharm S.A.	Composicion farmaceutica oral de desmopresina.
WO2009114226A1 (en) *	2008-03-11	2009-09-17	Mallinckrodt Inc.	Use of magnesium stearate dihydrate for lubrication of solid pharmaceutical compositions
US11963995B2 (en)	2008-05-21	2024-04-23	Ferring B.V.	Methods comprising desmopressin
US20100286045A1 (en)	2008-05-21	2010-11-11	Bjarke Mirner Klein	Methods comprising desmopressin
NO3085381T3 (pl) *	2008-05-21	2018-09-15
EP2345689B1 (en) *	2008-09-30	2017-04-12	Mitsui Chemicals, Inc.	Fiber-reinforced resin composition and molded object thereof
JP2022130075A (ja) *	2021-02-25	2022-09-06	フロイント産業株式会社	顆粒及びその製造方法、並びに錠剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8306367L (sv) *	1983-11-18	1985-05-19	Ferring Ab	Antidiuretiskt verkande farmaceutiskt preparat
US4675188A (en) *	1985-08-02	1987-06-23	Stauffer Chemical Company	Granular anhydrous dicalcium phosphate compositions suitable for direct compression tableting
US4820627A (en) *	1986-03-24	1989-04-11	Em Diagnostic Systems, Inc.	Method of preparing particles suitable for tabletting into diagnostic reagents
UA37214C2 (uk) *	1991-01-30	2001-05-15	Дзе Веллкам Фаундейшн Лімітед	Таблетки, що диспергуються у воді, та спосіб їх виготовлення
US5482931A (en)	1993-06-29	1996-01-09	Ferring Ab	Stabilized pharmaceutical peptide compositions
WO1995018602A1 (en)	1994-01-11	1995-07-13	Alkermes Controlled Therapeutics, Inc.	ORAL DOSAGE FORM OF DESMOPRESSIN (dDAVP)
SE9400918L (sv) *	1994-03-18	1995-09-19	Anne Fjellstad Paulsen	Stabiliserad komposition för oral administrering av peptider
US5849322A (en)	1995-10-23	1998-12-15	Theratech, Inc.	Compositions and methods for buccal delivery of pharmaceutical agents
GB9526495D0 (en)	1995-12-23	1996-02-28	Knoll Ag	Therapeutic agents
DE19602757A1 (de) *	1996-01-26	1997-07-31	Boehringer Mannheim Gmbh	Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung
SE9604341D0 (sv) *	1996-11-26	1996-11-26	Ferring Bv	Hepta-peptide oxytocin analogue
WO2000009423A1 (es)	1998-08-11	2000-02-24	Jaime Marti Sala	Silo para almacenamiento de cuerpos huecos ligeros
AT409081B (de)	2000-02-16	2002-05-27	Gebro Pharma Gmbh	Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
GB0009469D0 (en) *	2000-04-17	2000-06-07	Vectura Ltd	Improvements in or relating to formalities for use in inhaler devices
JP2004500424A (ja)	2000-04-17	2004-01-08	ヴェクトゥラ　リミテッド	吸入器で使用するための製剤
PE20011227A1 (es) *	2000-04-17	2002-01-07	Chiesi Farma Spa	Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0010709D0 (en)	2000-05-03	2000-06-28	Vectura Ltd	Powders for use a in dry powder inhaler
ES2292598T3 (es)	2000-06-27	2008-03-16	Vectura Limited	Metodo para producir particulas para usar en una composicion farmaceutica.
KR100642976B1 (ko) *	2001-05-10	2006-11-10	아스텔라스세이야쿠 가부시키가이샤	구강내 신속 붕괴성 정제 및 이의 제조방법
CA2460132A1 (en)	2001-10-15	2003-04-24	Roehm Gmbh & Co. Kg	Use of a copolymer to produce a galenic form containing a peptide or a protein as active agent
DE60307082D1 (de)	2002-05-07	2006-09-07	Ferring Bv	In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin
ATE291419T1 (de) *	2003-04-30	2005-04-15	Ferring Bv	Feste dosierungsform mit desmopressin
US7094545B2 (en) *	2003-04-30	2006-08-22	Ferring Bv	Pharmaceutical composition as solid dosage form and method for manufacturing thereof

2003
- 2003-07-25 AT AT03016945T patent/ATE301990T1/de active
- 2003-07-25 EP EP03016945A patent/EP1500390B1/en not_active Revoked
- 2003-07-25 PT PT03016945T patent/PT1500390E/pt unknown
- 2003-07-25 US US10/626,857 patent/US7022340B2/en not_active Expired - Fee Related
- 2003-07-25 ES ES03016945T patent/ES2243840T3/es not_active Expired - Lifetime
- 2003-07-25 DE DE60301351T patent/DE60301351T2/de not_active Expired - Lifetime
- 2003-07-25 SI SI200330100T patent/SI1500390T1/sl unknown
- 2003-07-25 DK DK03016945T patent/DK1500390T3/da active
2004
- 2004-07-19 KR KR1020057006309A patent/KR20050104331A/ko not_active Ceased
- 2004-07-19 JP JP2006520833A patent/JP4430673B2/ja not_active Expired - Fee Related
- 2004-07-19 AU AU2004260625A patent/AU2004260625B2/en not_active Ceased
- 2004-07-19 PL PL379704A patent/PL379704A1/pl not_active Application Discontinuation
- 2004-07-19 CA CA002490335A patent/CA2490335C/en not_active Expired - Fee Related
- 2004-07-19 WO PCT/EP2004/051538 patent/WO2005011640A2/en not_active Ceased
- 2004-07-19 NZ NZ544104A patent/NZ544104A/en not_active IP Right Cessation
- 2004-07-19 RU RU2005141230/15A patent/RU2303439C2/ru not_active IP Right Cessation
- 2004-07-19 MX MXPA06000903A patent/MXPA06000903A/es active IP Right Grant
- 2004-07-19 BR BRPI0412905-9A patent/BRPI0412905A/pt not_active Application Discontinuation
- 2004-07-23 TW TW093122090A patent/TWI268782B/zh not_active IP Right Cessation
2005
- 2005-04-19 NO NO20051896A patent/NO327328B1/no not_active IP Right Cessation
2007
- 2007-11-22 IL IL187591A patent/IL187591A0/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
BRPI0412905A (pt)	2006-09-26
WO2005011640A2 (en)	2005-02-10
RU2005141230A (ru)	2006-07-10
US7022340B2 (en)	2006-04-04
JP4430673B2 (ja)	2010-03-10
ATE301990T1 (de)	2005-09-15
AU2004260625A1 (en)	2005-02-10
EP1500390A1 (en)	2005-01-26
PT1500390E (pt)	2005-10-31
EP1500390B1 (en)	2005-08-17
HK1072009A1 (en)	2005-08-12
MXPA06000903A (es)	2006-05-04
DK1500390T3 (da)	2005-09-19
DE60301351D1 (de)	2005-09-22
NZ544104A (en)	2008-06-30
KR20050104331A (ko)	2005-11-02
US20050019392A1 (en)	2005-01-27
TW200509995A (en)	2005-03-16
NO327328B1 (no)	2009-06-08
SI1500390T1 (sl)	2006-02-28
ES2243840T3 (es)	2005-12-01
WO2005011640A3 (en)	2005-03-24
AU2004260625B2 (en)	2007-12-06
RU2303439C2 (ru)	2007-07-27
JP2007517762A (ja)	2007-07-05
IL187591A0 (en)	2008-03-20
NO20051896L (no)	2005-04-19
TWI268782B (en)	2006-12-21
CA2490335C (en)	2006-01-31
DE60301351T2 (de)	2006-01-19
CA2490335A1 (en)	2005-01-25

Legal Events

Date	Code	Title	Description
2013-10-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
IL187591A0 (en)	2008-03-20	Pharmaceutical composition as solid dosage from and method for manufacturing thereof
TW200518743A (en)	2005-06-16	Rapid dissolution formulation of a calcium receptor-active compound
TW200505406A (en)	2005-02-16	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
WO2003022809A3 (en)	2003-07-17	Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
MY148773A (en)	2013-05-31	Galenic formulations of organic compounds
DE60104399D1 (de)	2004-08-26	Pulverformulierung zur inhalation
GEP20074208B (en)	2007-10-10	Substituted amides active at the cannabinoid-1 receptor
WO2006024486A3 (en)	2006-05-26	Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
WO2003048164A3 (en)	2003-10-16	Adenosine a2a receptor antagonists
EA200301040A1 (ru)	2004-04-29	Способ производства фармацевтической композиции низкой дозы
ATE329581T1 (de)	2006-07-15	Pharmazeutische formulierung, die n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydr -2h-(1, 3)oxazino(3,2-a)indol-10-carboxamid oder ein entsprechendes salz hiervon enthält, sowie deren herstellungsprozess, welcher trockengranulierung beinhaltet
WO2005075450A3 (en)	2006-03-30	Spiro-benzodioxoles and their use as cb1 antagonists
TW200640465A (en)	2006-12-01	New pharmaceutically active compounds for the treatment of respiratory diseases
BE2016C017I2 (pl)	2021-07-19
WO2004048381A3 (en)	2004-08-05	Pyrazoloazepine compounds as pharmaceutical agents
SI1473029T1 (en)	2005-10-31	Solid dosage form comprising desmopressin
IL163025A (en)	2010-06-16	Prucalopride - n - oxides, their preparation and pharmaceutical compositions comprising them
CY1114949T1 (el)	2016-12-14	Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson